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Binding-Site Flexibility and Multiple Binding Modes of the
Natural Ligand Acetyl-Lysine
Dimitrios Spiliotopoulos* and Amedeo Caflisch*[a]
1. Introduction
The number of protein structures solved by X-ray crystal-
lography and/or NMR spectroscopy has grown almost ex-
ponentially since the determination of the first protein
structure.[1] Despite their unquestionable usefulness, ex-
perimentally determined structures lack most of the infor-
mation concerning the dynamic behavior of a protein. Ri-
chard P. Feynman acutely observed in 1963, “One of the
great triumphs in recent times (since 1960), was at last to
discover the exact spatial atomic arrangement of certain
proteins […]. One of the sad aspects of this discovery is
that we cannot see anything from the pattern; we do not
understand why it works the way it does.”[2] Indeed, pro-
tein motions are often essential for protein function.[3]
This is particularly true for proteinligand interactions, as
the current binding models assume that conformational
rearrangements (including random thermal motions)
occur at both the protein and the ligand level.[4] There-
fore, both structural and thermodynamic properties of the
interaction are affected. NMR order parameters and calo-
rimetric measurements can provide insights into protein
motion at the residue level and free energy difference
upon binding, respectively. However, their limitations
hamper the full understanding of the biochemical pro-
cesses.[5] Molecular dynamics (MD) simulations can fill
this void (“the next problem to be attacked”, in Feyn-
mans words)[2] by assisting in the interpretation of exper-
imental data and guiding further experiments.[3]
Historically, classical MD simulations (i.e., the tempo-
ral evolution of a set of atoms according to Newtons
second law of motion) have been performed starting from
the 1950s, when liquid systems consisting of relatively few
atoms were simulated with hard[6] and then soft[7] spheres.
An important progress was the simulation of liquid water,
the first polar molecule, in the early 1970s.[8] Chemists
questioned the feasibility of such an approach on a protein
structure, and biologists its utility.[9] The first MD simula-
tion of a protein was carried out in the group of Martin
Karplus in 1977.[10] The available computational resources
at the time limited the simulation in terms of time
(9.2 ps), amount of atoms (the protein under investigation,
i.e., bovine pancreatic trypsin inhibitor, had been chosen
also because of its small size) and solvent (the protein was
simulated in vacuo). Significant methodological develop-
ments in terms of algorithms for MD sampling and force
field parameterization as well as the ever improving com-
puter hardware have characterized the past forty years.[11]
A wide variety of MD techniques and force fields are con-
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Abstract : Experimental protein structures provide spatial in-
formation at the atomic level. A further dimension, time, is
supplemented by molecular dynamics. Since the pioneering
work on the 58-residue inhibitor of bovine pancreatic trypsin
in the group of Martin Karplus in the seventies, molecular
dynamics simulations have shown that the intrinsic flexibili-
ty of proteins is essential for their function. Here, we review
simulation studies of bromodomains. These protein mod-
ules are involved in the recognition of acetylated lysine side
chains, a post-translational modification frequently observed
in histone tails. The molecular dynamics simulations have
unmasked: (i) the large plasticity of the loops lining the
acetyl-lysine binding site (coupled to its self-occlusion), and
(ii) multiple binding modes of acetyl-lysine. These simula-
tion results suggest that recognition of histone tails by bro-
modomains is modulated by their intrinsic flexibility, and
further corroborate the utility of molecular dynamics in un-
derstanding (macro)molecular recognition.
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stantly being developed and improved,[12] and the first mi-
crosecond-[13] and millisecond-long[14] MD simulations were
reported within slightly more than a decade.
Experimental data are still necessary to validate the
computer simulations.[9] In 1975, B. Honig, A. Warshel
and M. Karplus wrote that, “theoretical chemists tend to
use the word prediction rather loosely to refer to any
calculation that agrees with experiment, even when the
latter was done before the former.”[15] Agreement with
available experimental data unquestionably provides an
a posteriori validation of the simulation model and justi-
fies the in-depth analysis of the MD trajectories which
reach temporal and spatial resolutions not accessible to
experimental approaches. That being said, it must be
stressed that there is a continuous increase in the number
of in silico investigations that formulate predictions in the
true meaning of the word. These computational results
provide insights that are used to guide experimental ef-
forts. The predictive ability of atomistic simulations has
played key roles in a wide variety of applications, most
notably drug discovery[16] and protein engineering.[17] This
highlights the prominent role of biomolecular modeling
and simulations not only in basic but also in application-
oriented research. Indeed, simulation techniques based
on classical mechanics (ranging in complexity from
simple energy minimization up to sophisticated enhanced
sampling MD techniques) are used more and more by re-
search groups consisting mainly of experimentalists. Con-
firming the adult state of the field and its widespread use,
some authors have highlighted the necessity to be well
aware of the caveats of biomolecular modeling and simu-
lation tools.[11,18]
In the following sections, we will describe the advances
in the understanding of the dynamic properties of bromo-
domains, a class of protein modules involved in epigenetic
processes that has gained increasing importance in the
last years. The combinatorial arrangement of the histone
post-translational modifications (PTMs) was suggested to
contribute to the regulation of DNA-templated processes,
such as gene expression and DNA replication.[19] This hy-
pothesis, termed “histone code”, is now widely accepted.
Among the histone PTMs, the acetylation of the e-amino
group of lysine residues (first described 50 years ago)[20]
plays a key role in the epigenetic regulation of gene ex-
pression. The acetyl group is covalently added and re-
moved by histone acetyltransferases (HATs) and histone
deacetylases (HDAC), respectively.[21] Upon acetylation
the positive charge of the lysine side chain is abolished,
which directly impairs the histone electrostatic interac-
tions with DNA. It is thus not surprising that histone
lysine acetylation has been related (although not exclu-
sively) to open or active chromatin regions.[22] This his-
tone PTM also selectively recruits a set of acetyl-lysine
binding protein modules[21] which stabilize the binding of
further machineries to mediate the indirect effects of the
modification.[23] Bromodomains constitute the major
group of acetyl-lysine interacting modules.
Bromodomains present four helices (aZ, aA, aB, aC)
folded into a left-handed bundle.[24] The ZA and BC
loops, connecting the former two and latter two helices,
respectively, line the opening of the acetyl-lysine binding
pocket.[25] This pocket contains three conserved residues:
two tyrosine residues (one in each of the ZA loop and
BC loop), whose side chains constitute the hydrophobic
pocket, and an asparagine residue, lying immediately
downstream of the second conserved tyrosine residue,
which secures the acetyl moiety of the acetylated lysine
via a hydrogen bond.[26]
The implication of histone acetylation in the develop-
ment and progression of human diseases is well estab-
lished and two HDAC inhibitors are currently used in
clinical practice.[27] Target-based drug design investiga-
tions have so far mainly focused on epigenetic enzymes,
i.e. , “writers” or “erasers”, possibly as a result of the al-
legedly limited druggability of proteinprotein interac-
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tions[28] and due to the utilization of enzymatic assays,
which can be easily used for small-molecule screening
and lead optimization chemistry.[29] Epigenetic “readers”
have recently emerged as legitimate targets for drug dis-
covery. Filippakopoulos and colleagues described a small
molecule, JQ1, which acts as a potent and selective inhibi-
tor of the histone binding activity of the bromodomains
belonging to the BET family, most notably the BRD4
first bromodomain.[30] BRD4 is a fused component of
a chimeric protein (BRD4-NUT) associated with an ag-
gressive and incurable form of carcinoma. JQ1 was
proven to be acetyl-lysine competitive in cell-based
assays, which resulted in an anti-proliferative effect in
BRD4-dependent cancer cell lines and patient-derived
xenograft models.[30] In the same issue, Nicodeme and co-
workers reported I-BET, a pan-BET inhibitor that effi-
ciently suppressed the expression of a subset of lipopoly-
saccharide-induced genes in LPS-treated bone marrow
derived macrophages by interfering with BET bromodo-
main recruitment to the corresponding chromatin regions.
Of note, prophylactic and therapeutic administration of I-
BET in mouse models of sepsis resulted in an increased
survival.[31] Importantly, structural and biophysical investi-
gations provided in both papers the rationale of the
ligand binding specificity and these compounds were
readily made available for the scientific community.
These works provided a proof of concept that a new
series of targets for epigenetic drugs, the reader modules,
can be used: since proteinprotein interactions underpin
all epigenetic mechanisms, the target availability is im-
mense. As a matter of fact, numerous works have recent-
ly identified selective bromodomain inhibitors.[32] For this
purpose, features such as small structural differences be-
tween the proteins to be targeted[33] and their dynamics[34]
cannot be ignored, making it imperative to perform com-
putational investigations on bromodomains.
Despite their importance, few simulation studies had
been performed on bromodomains until recently.[35] Here
we review how recent MD simulations have shed light on
the flexibility of bromodomains in their free state and in
complex with their physiological ligand.[36] The simula-
tions add the temporal dimension to the static picture
provided by the many crystal and NMR structures of bro-
modomains. Binding-site flexibility and multiple binding
modes emerge thanks to the MD studies.
2. MD Reveals Bromodomain Binding-Site
Flexibility and Self-Occlusion
Despite the wealth of available three-dimensional struc-
tures of human bromodomains,[37] little is known about
their flexibility and relative plasticity among different
families. This hampers the comprehension of the bromo-
domainhistone tail physiological interactions as differen-
ces in selectivity might originate in part from the differen-
ces in intrinsic flexibility. Moreover, a complete under-
standing of the different dynamics of the individual do-
mains would have crucial relevance for the design of
drugs selectively targeting specific bromodomains. These
considerations prompted the computational analysis of
the binding-site flexibility of 20 bromodomains (repre-
senting seven of the eight families of human bromodo-
mains) by means of MD simulations.[36b]
At 310 K the folded state of all simulated bromodo-
mains is stable over a 1 ms time scale[36b] and even along
10 ms runs (Huang and Caflisch, unpublished results). The
sequence profile of the root mean square fluctuations
(RMSF), which reports on the flexibility on the nanosec-
ond time scale, indicates that the fluctuations are largest
for the ZA loop, BC loop, and the termini in all simula-
tions of bromodomains, as shown for the CREBBP bro-
modomain in Figure 1B,D.
In striking contrast, the crystallographic B-factors sug-
gest a relatively uniform flexibility along the bromodo-
main backbone, with a slightly larger disorder only at the
N- and C-termini (Figure 1A,C). This comparison shows
that the degree of flexibility of the ZA loop and BC loop
with respect to the rest of the domain is strongly underes-
timated by the experimental data, mainly due to spurious
contacts involving the loop residues and neighboring mol-
ecules in the crystal arrangement.[36b] Since these loops
line the acetyl-lysine binding site, their fluctuations are
very likely to affect the biological function of the bromo-
domain, i.e., the specific recognition of the acetylated
lysine and binding of histone tails.
The bromodomain acetyl-lysine binding pocket con-
tains three highly evolutionarily conserved residues (Fig-
ure 1C,D). An Asn is present in the BC loop of most bro-
modomains: co-crystal structures showed that its side
chain amide establishes a hydrogen bond with the oxygen
atom of the acetyl group of the acetyl-lysine.[38] Two Tyr
residues, lying in the ZA loop and BC loop, partake in
the formation of the hydrophobic pocket constituting the
binding site.[26] The MD simulations showed that the
motion of the residues adjacent to the conserved Asn in-
fluences directly the accessibility of the acetyl-lysine bind-
ing site. In particular, the trajectories of some of the 20 si-
mulated bromodomains reveal a significant flexibility of
the side chain of the highly conserved Tyr in the BC loop
(corresponding to a Phe in BAZ2B and SMARCA4).[36b]
This Tyr (or Phe) residue is upstream in the sequence to
the Asn that is involved in the binding to the acetylated
lysine. Its aromatic side chain rotates from an orientation
towards the center of the binding site to an outward ori-
entation in which it points towards the solvent (Figure 2,
top). Interestingly, this conformation is present in only
a few apo bromodomain crystal and solution structures,
i.e. , the bromodomains of BRDT(1) and KIAA1240
(PDB codes 2RFJ and 2DKW, respectively).[36b] In the
MD simulations of BAZ2B and CREBBP, the swapping
out of the conserved Tyr in the BC loop results in the re-
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arrangement of the side chains of other residues forming
the binding site, which ultimately leads to the partial oc-
clusion of the binding pocket (Figure 2, bottom).
The outward reorientation is often accompanied by
large fluctuations of the ZA loop, with the establishment
of a hydrogen bond between the side chains of the two
conserved residues, the BC loop Asn and the ZA loop
Tyr.[36b] In this conformation, the ZA loop Tyr side chain
mimics the acetylated lysine, by occupying its position
and being anchored with a hydrogen bond to the side
chain amide of the conserved Asn. The self-occluding re-
arrangement of this residue might constitute a fine autor-
egulatory mechanism for acetyl-lysine binding. This slight
alteration of the binding site is comparable to other well-
studied cases of intra-steric regulation involving more
dramatic conformational rearrangements, such as the as-
partic protease[39] and protein tyrosine kinases.[40] The
subtlety of this switch could be correlated to the necessity
of bromodomains to be readily recruited to and released
from chromatin, similar to other epigenetic readers such
as PHD fingers,[41] and would account in part for the rela-
tively low affinity of the bromodomains towards histone
tails. Additionally, this rearrangement might also facilitate
the release of the ligand. A similar example of a molecular
shovel mechanism has been found in the Trypanosoma
cruzi trans-sialidase, whose Trp312 side chain displaces
the donor aglycone from the active site.[42]
It is not unprecedented that MD simulations have re-
vealed altered accessibilities in the binding sites of apo
proteins.[43] The partial occlusion of the binding site ob-
served in the MD simulations of the BAZ2B and
CREBBP bromodomains is related to a displacement of
the ZA loop, which has remarkable differences in length
and sequence in the 61 human bromodomains.[37] This
prompts further investigations to assess to what extent
this self-occluded metastable state is present in other bro-
modomains. Analogous alterations in the binding-site ac-
cessibility could be present in other epigenetic readers.
For example, it has been shown that the binding to his-
tone tails of the PHD finger of the human and Drosophi-
la Pygo proteins is enhanced by an alteration of the shape
and/or the stability of the binding pocket. In this case, the
rearrangement results from the simultaneous interaction
with another protein, which binds to a distinct surface of
the PHD finger.[44] On a more application-oriented note,
the knowledge of alternative conformation(s) of the bro-
modomain binding pocket will play a key role in the
design of selective inhibitors.
Figure 1. MD simulations show pronounced flexibility of the ZA loop lining the acetyl-lysine binding site of bromodomains. (A) Sequence
profile of the measured crystallographic B-factors (PDB code 3DWY) and (B) RMSF values along MD runs at 310 K of the CREBBP bromodo-
main. The RMSF values were averaged over 5 ns long simulation intervals. (C,D) Tube-like representation of the CREBBP bromodomain. The
evolutionarily conserved Tyr and Asn residues are shown as sticks, while the N- and C-termini are indicated by blue and red spheres, re-
spectively. The thickness of the tube is related to the B-factors (C) and the RMSF values (D).
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3. MD Reveals Multiple Binding Modes of Acetyl-
Lysine
The reversible binding of acetyl-lysine to the second bro-
modomain of the human TAF1 (TAF1(2); PDB code
3UV4) has been studied by unbiased MD simulations.[36a]
This study reports on the first simulations of the binding
of a post-translationally modified residue to an epigenetic
reader module. Twenty-four independent MD runs were
started after placing the acetylated lysine in a random po-
sition at a distance of more than 20  from the bromodo-
main. Spontaneous binding of the ligand to the acetyl-
lysine pocket was observed in 16 of the 24 trajectories on
a 500 ns time scale; in some cases the entrance of the ace-
tylated lysine into the binding pocket was followed by an
unbinding event.
Upon spontaneous binding to the TAF1(2) bromodo-
main in the simulations, the acetyl-lysine adopted the
binding mode observed in the co-crystal structures,
named the “N-binding mode”[36a] (Figure 3, left). The MD
trajectories revealed that this conformation reversibly
converted into a more buried binding pose, which has
been called the “P-binding mode”. In this pose, the
oxygen atom of the backbone carbonyl of the proline of
the so-called WPF shelf (a Trp-Pro-Phe motif in the ZA
loop) acts as acceptor for a hydrogen bond with the Nz
atom of the acetylated lysine (Figure 3, right). Interesting-
ly, this previously unknown conformation was slightly
more populated than the N-binding mode.[36a] The cut-
based free energy profile method[45] isolated a third meta-
stable conformation, the “P/N-intermediate”. The mean
first-passage time indicated that the interconversion be-
tween the P- and N-binding modes is relatively fast
(20 ns) with respect to the (un)binding events (220–
320 ns).[36a]
Alternative binding modes are an essential feature of
proteinprotein interactions.[46] NMR spectroscopy[47] and
X-ray crystallography[48] approaches have been described
to capture transiently populated conformations. Nonethe-
less, experimental techniques suffer from only reporting
a few properties, which are relatively poorly resolved
averages over time and space.[49] Conversely, the insights
provided by computational techniques are mainly limited
by sampling errors, i.e., atomistic MD simulations might
not reach the time scales required for certain fundamen-
tal processes, such as folding of large proteins. Another
limitation (which plays a key role in in silico screening) is
the limited accuracy in binding affinity calculations.[50]
Figure 2. (Top) Two representative snapshots extracted from the
MD simulations of CREBBP show the swapping out of the side
chain of the Tyr residue preceding the conserved Asn in the BC
loop. The dashed line indicates the hydrogen bond between the
Asn and the Tyr in the ZA loop. (Bottom) Surface representation of
the crystal structure of CREBBP (PDB code 3P1C; left) and of a rep-
resentative MD snapshot with a partially occluded, i.e. , shallower,
binding site (right). The colors of the boxes correspond to those in
the two structures in the top panel while the color coding of the
surface reflects atomic elements (carbon, nitrogen, and oxygen
atoms in yellow, blue, and red, respectively). The location of the
acetyl-lysine binding site is indicated with a black oval. Figure and
legend adapted from reference [36b].
Figure 3. The two major binding modes of acetyl-lysine in the
CREBBP bromodomain as observed in MD simulations of spontane-
ous binding. The N-binding mode (left) corresponds to the crystal
structure, while the P-binding mode (right) emerges from the MD
simulations and has not yet been reported in experimental studies.
The thickness of the arrows reflects the number of direct transi-
tions between states in the MD runs, i.e. , the interconversions be-
tween N- and P-binding modes are much more frequent than the
binding or unbinding process.[36a] Figure adapted from reference
[36a].
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Nonetheless, atomistic simulations can provide insights
that are elusive to experimental approaches. Modeling
and simulations have unveiled multiple binding modes in
other systems, in some cases being confirmed by experi-
mental data.[51] In this context, it is noteworthy that after
the discovery by means of unbiased MD simulations of
the acetyl-lysine “P-binding mode” in the TAF1(2) bro-
modomain,[36a] two independent studies have reported in-
hibitors targeting different bromodomains that exhibited
a similar binding pose with a hydrogen bond to the car-
bonyl oxygen of the Pro in the WPF shelf.[32j,l]
4. Other MD Studies of Binding
Historically, the vast majority of computational studies
addressing molecular recognition have focused on the in-
vestigation of the end points of the binding process. This
means that only the free molecular species and the com-
plex are analyzed, either in their experimentally deter-
mined conformation or in their docked lowest energy
pose. This two-state approach is inadequately oversimpli-
fied.[52] The intrinsic plasticity of proteins is essential in
many cases for their function,[53] including enzyme-cata-
lyzed reactions[54] and molecular recognition.[55] Upon
binding to a ligand, proteins often experience a wide
range of movements[56] and alterations (either increases
or decreases) of backbone and side chain flexibility.[57] As
a result, the free and bound conformations of a target
protein can be different,[58] and small changes in the pro-
tein and solvent geometries can dramatically affect the af-
finity with a ligand.[51,57] Moreover, the entropic terms and
the changes in solvent structure, which play a crucial role
in many binding processes, are elusive to the static struc-
tures.[51] These observations ultimately indicate that any
investigation focusing on a single structure is possibly in-
complete, and thus error-prone.
Protein flexibility can be inferred from experimental
data, such as crystallographic B-factors[59] and NMR spin
relaxation data.[60] The former include also static disorder
in the crystal, however, while the latter report on an en-
semble of molecules. Atomistic biomolecular simulations
provide a detailed, single-molecule description of protein
motion[61] as a full continuum of conformations[56] from
the fs to ms time scales,[3,49d] making them a powerful tool
for investigating protein function. MD simulations have
revealed that intrinsic protein flexibility governs (un)-
binding of the natural ligands,[62] substrates/products,[63] or
drugs.[64] In particular, simulations have provided valuable
insights for a number of small protein-interacting mod-
ules in their interaction with their physiological ligands or
small molecules. These protein domains are involved in
a wide variety of biological processes, such as epigenet-
ics,[65] signal transduction,[66] and apoptosis.[67] A computa-
tional clarification might even settle unclear experimental
results. For example, the discovery of multiple metastable
states of the ligand in silico has also shed light onto dis-
crepancies in the experimentally determined binding
modes, as reported for the Staphylococcus aureus Sortase
A interaction with the LPATG sorting signal.[68] Atomistic
simulations can also provide information when the exper-
imental data are missing, as shown by Smith and co-work-
ers: three MD-based strategies were devised to identify
the binding modes of palmitate to the barley lipid transfer
protein where the NOE restraints were not sufficient to
clearly define the details of the ligand binding site.[69]
Recent studies indicate that interactions occurring
away from the active site[70] or the expected binding
site[71] can affect the protein specificity and/or activity.
Enhanced sampling techniques have been used to explore
the ligand diffusion processes, including steered MD,[72]
random acceleration MD,[73] metadynamics,[74] Monte
Carlobased approaches[75] and conformational sampling
methods inspired by robot motion planning algorithms.[76]
Unbiased MD simulations have generated thermodynam-
ic (dissociation constant) and kinetic (on and off rates)
data for complex formation. Moreover, they have success-
fully illustrated the binding pathways for small molecules
and drugs to protein targets, either using massive compu-
tation[77] or performing multiple MD runs with a high
(i.e., mM) concentration of ligand in the simulation
box.[49c] Interestingly, two features highlighted by the
computational studies on bromodomains are common to
other systems: (i) the presence of metastable states corre-
sponding to alternative binding poses, and (ii) the crucial
importance of solvent molecules in molecular recogni-
tion.[78]
5. Summary and Outlook
Small molecules specifically inhibiting the acetyl-lysine
binding activity of bromodomains have been identified
and characterized since 2005.[79] The usefulness of such
chemical probes has been extensively described in the
past.[32a,80] As noted by several authors,[32k,80a] the dynamic
properties of bromodomains should not be ignored to ef-
ficiently target their acetyl-lysine binding activity. None-
theless, information on the flexibility of bromodomains
and the dynamicity of their interaction with the ligands
was limited. The recent computational investigations have
revealed key features of these important protein modules,
i.e. , (i) the flexibility of the loops and its potential impact
on histone tail recognition,[36b] and (ii) the multiple bind-
ing modes of the acetylated lysine.[36a] We wish to stress
that these important findings relate with preceding and
subsequent experimental observations. The high flexibili-
ty of the ZA and BC loops (highlighted for the CREBBP
bromodomain by NMR data and preliminary MD simula-
tions[80a] but underestimated by the crystallographic B-fac-
tors), has been quantified recently.[36b] A novel acetyl-
lysine binding mode, described for the first time in silico,
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has been supported by similar interactions in recently de-
scribed bromodomain ligands.[32j,l] These findings lead one
to speculate that the protein plasticity of epigenetic read-
ers might constitute an additional layer of regulation in
the dynamic processes mediating epigenetic processes.
This could also apply for epigenetic erasers and writers,
as hypothesized for the SET and postSET domains of
NSD1.[81] These questions will be addressed by a combina-
tion of carefully selected and expertly applied computa-
tional, biochemical and functional approaches to be un-
dertaken in the future.
Modeling protein flexibility is currently a major chal-
lenge in the theoretical investigations of proteinligand
interactions.[82] Legitimate optimism for further advances,
recently fueled by the enthusiasm kindled by the 2013
Nobel Prize in Chemistry,[83] accompanies the efforts to-
wards this goal and invigorates the advances of computa-
tional techniques aimed to describe long-time-scale pro-
cesses. Clearly, unbiased MD simulations are not yet suit-
able for high-throughput virtual screenings, due to their
excessive computational cost.[84] A major challenge for
drug design and development will be the investigation of
binding and unbinding kinetics, as these might play a sig-
nificant role in drug efficacy and safety. Significant advan-
ces are constantly granted by technological progresses in
hardware (as the use of graphics processing units[84] or ad
hoc computer architectures[14]) and software. It will none-
theless be crucial to further improve enhanced sampling
techniques, such as those mentioned earlier in this review,
accelerated MD,[85] the free energy guided sampling
(FEGS),[86] and multi-scale approaches.[83] Both basic re-
search and drug design will benefit as, once mastered, this
expertise will allow researchers to identify drug-targeta-
ble protein metastable states, including allosteric sites in-
visible in experimental structures.[77] Future advances in
both experimental and computational structural biology
aimed to increase their interplay (e.g., in reference [87])
will constitute a fundamental step for their mutual benefit
in the understanding of biomolecular recognition.
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